{
  "documents": [
    {
      "guide": "ccsstemi2019",
      "title": "2019 CCS/CAIC STEMI Reperfusion Update",
      "guideline_url": "https://onlinecjc.ca/article/S0828-282X%2818%2931321-7/fulltext",
      "keywords": [
        "STEMI",
        "ST-elevation myocardial infarction",
        "reperfusion",
        "primary PCI",
        "thrombolysis",
        "regionalization",
        "STEMI system of care",
        "PCI networks",
        "time-to-reperfusion",
        "complications",
        "secondary prevention"
      ]
    },
    {
      "guide": "ccslipid2021",
      "title": "2021 CCS Dyslipidemia Prevention Guideline",
      "guideline_url": "https://onlinecjc.ca/article/S0828-282X(21)00165-3/fulltext",
      "keywords": [
        "dyslipidemia",
        "lipids",
        "LDL",
        "non-HDL",
        "risk assessment",
        "Framingham Risk Score",
        "lifestyle",
        "pharmacotherapy",
        "nonstatin",
        "lipoprotein(a)",
        "Lp(a)",
        "coronary artery calcium",
        "CAC",
        "women",
        "hypertensive disorders of pregnancy"
      ]
    },
    {
      "guide": "ccshfnref2025",
      "title": "2025 CCS/CHFS Guideline for HFnrEF",
      "guideline_url": "https://onlinecjc.ca/article/S0828-282X%2825%2900640-3/fulltext",
      "keywords": [
        "heart failure",
        "HFnrEF",
        "HFpEF",
        "HFmrEF",
        "nonreduced ejection fraction",
        "LVEF > 40%",
        "preserved EF",
        "mildly reduced EF",
        "SGLT2 inhibitor",
        "MRA",
        "mineralocorticoid receptor antagonist",
        "ARNI",
        "angiotensin receptor-neprilysin inhibitor",
        "GLP-1 receptor agonist",
        "pharmacologic management"
      ]
    },
    {
      "guide": "ccshfref2021",
      "title": "2021 CCS/CHFS Guideline for HFrEF",
      "guideline_url": "https://onlinecjc.ca/article/S0828-282X(21)00055-6/fulltext",
      "keywords": [
        "heart failure",
        "HFrEF",
        "reduced ejection fraction",
        "quadruple therapy",
        "GDMT",
        "ARNI",
        "beta-blocker",
        "beta blocker",
        "MRA",
        "SGLT2 inhibitor",
        "initiation",
        "titration",
        "mortality",
        "heart failure hospitalization"
      ]
    },
    {
      "guide": "ccsvtvf2020",
      "title": "2020 CCS/CHRS VT/VF Structural Heart Disease",
      "guideline_url": "https://onlinecjc.ca/article/S0828-282X%2820%2930326-3/fulltext",
      "keywords": [
        "ventricular tachycardia",
        "VT",
        "ventricular fibrillation",
        "VF",
        "structural heart disease",
        "sustained VT",
        "sudden cardiac death",
        "ICD",
        "implantable cardioverter defibrillator",
        "risk stratification",
        "antiarrhythmic",
        "catheter ablation"
      ]
    }
  ]
}
